A phase 2 repeat dosing clinical trial of SB-509 [Sangamo BioSciences] in subjects with diabetic neuropathy.

Trial Profile

A phase 2 repeat dosing clinical trial of SB-509 [Sangamo BioSciences] in subjects with diabetic neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs SB 509 (Primary)
  • Indications Diabetic neuropathies
  • Focus Therapeutic Use
  • Sponsors Sangamo BioSciences
  • Most Recent Events

    • 30 Jun 2010 Results reported at 70th Annual Scientific Sessions of the American Diabetes Association (ADA), according to a Sangamo media release.
    • 29 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top